Zacks Research Downgrades Repligen (NASDAQ:RGEN) to Hold

Repligen (NASDAQ:RGEN) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks reports.

Several other research analysts have also weighed in on the company. Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th. HSBC decreased their target price on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Wolfe Research began coverage on Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price for the company. JPMorgan Chase & Co. boosted their price target on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Evercore reissued an “outperform” rating and issued a $160.00 price target on shares of Repligen in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $168.57.

Repligen Price Performance

Repligen stock opened at $194.57 on Monday. The stock’s 50 day moving average is $167.55 and its 200 day moving average is $140.04. Repligen has a one year low of $100.99 and a one year high of $198.87. The firm has a market cap of $10.98 billion, a P/E ratio of 266.53, a P/E/G ratio of 3.54 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the previous year, the company earned $0.26 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, research analysts expect that Repligen will post 2.06 EPS for the current year.

Hedge Funds Weigh In On Repligen

Several large investors have recently added to or reduced their stakes in RGEN. ABS Investment Management LLC purchased a new stake in Repligen in the 2nd quarter valued at about $191,016,000. Angeles Wealth Management LLC increased its position in shares of Repligen by 6.6% during the second quarter. Angeles Wealth Management LLC now owns 2,757 shares of the biotechnology company’s stock valued at $376,000 after acquiring an additional 170 shares during the last quarter. State of Michigan Retirement System boosted its position in Repligen by 1.6% in the first quarter. State of Michigan Retirement System now owns 12,753 shares of the biotechnology company’s stock worth $1,503,000 after purchasing an additional 200 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in Repligen by 2.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 10,841 shares of the biotechnology company’s stock valued at $1,277,000 after purchasing an additional 300 shares during the period. Finally, KBC Group NV raised its stake in shares of Repligen by 20.7% during the 1st quarter. KBC Group NV now owns 1,837 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 315 shares during the period. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.